Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 188

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 188
---
 exercise by the holders thereof in consideration for their investment
in the Series C PIPE Financing.

The
Preferred Warrants prohibited us from entering into specified fundamental transactions unless the Successor assumes all of our obligations
under the Preferred Warrants under a written agreement before the transaction is completed. Upon specified corporate events, a holder
of the Preferred Warrants thereafter had the right to receive upon an exercise such shares, securities, cash, assets or any other property
whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the Preferred
Warrant been exercised immediately prior to the applicable corporate event.

During the six months ended June 30, 2025, the 625 remaining Series
A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for gross proceeds of $500,000. During the six months
ended June 30, 2024, no Series A Preferred Warrants were exercised into shares of Series A Preferred Stock.

The
Company’s Preferred Warrants were exercisable into Series A Preferred Stock, which had no cash redemption features that required
liability treatment. The Company recorded the Preferred Warrants as equity.

February
2025 Pre-funded Warrants and February 2025 Common Warrants

On February 5, 2025, in connection with the February 2025 Offering
(See Note 8), the Company sold (i) 15,000 shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to 112,551 shares of Common
Stock, and (iii) Common Warrants to purchase up to 127,551 shares of common stock, at a combined public offering price of $39.20 per share
and Warrant. During the three months ended March 31, 2025, 91,214 shares of its common stock were issued following the exercise of certain
Pre-Funded Warrants. During the three months ended June 30, 2025, 10,550 shares of its common stock were issued following the exercise
of certain Pre-Funded Warrants. At June 30, 2025, the remaining 10,787 Pre-Funded Warrants remain exercisable. The Pre-Funded Warrants
are exercisable at any time and have no expiration date

Additionally,
in connection with the February 2025 Offering, the Company issued the February 2025 Common Warrants to purchase up to 127,551 shares
of common stock with an exercise price of $